Mena<sup>calc</sup>, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer

Catherine L. Forse, Seema Agarwal, Dushanthi Pinnaduwage, Frank Gertler, John S. Condeelis, Juan Lin, Xiaonan (Nan) Xue, Kimberly Johung, Anna Marie Mulligan, Thomas E. Rohan, Shelley B. Bull, Irene L. Andrulis

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Mena<sup>calc</sup> is an immunofluorescence-based, quantitative method in which expression of the non-invasive Mena protein isoform (Mena11a) is subtracted from total Mena protein expression. Previous work has found a significant positive association between Mena<sup>calc</sup> and risk of death from breast cancer. Our goal was to determine if Mena<sup>calc</sup> could be used as an independent prognostic marker for axillary node-negative (ANN) breast cancer. Methods: Analysis of the association of Mena<sup>calc</sup> with overall survival (death from any cause) was performed for 403 ANN tumors using Kaplan Meier survival curves and the univariate Cox proportional hazards (PH) model with the log-rank or the likelihood ratio test. Cox PH models were used to estimate hazard ratios (HRs) for the association of Mena<sup>calc</sup> with risk of death after adjustment for HER2 status and clinicopathological tumor features. Results: High Mena<sup>calc</sup> was associated with increased risk of death from any cause (P = 0.0199, HR (CI) = 2.18 (1.19, 4.00)). A similarly elevated risk of death was found in the subset of the Mena<sup>calc</sup> cohort which did not receive hormone or chemotherapy (n = 142) (P = 0.0052, HR (CI) = 3.80 (1.58, 9.97)). There was a trend toward increased risk of death with relatively high Mena<sup>calc</sup> in the HER2, basal and luminal molecular subtypes. Conclusions: Mena<sup>calc</sup> may serve as an independent prognostic biomarker for the ANN breast cancer patient population.

Original languageEnglish (US)
Article number483
JournalBMC Cancer
Volume15
Issue number1
DOIs
StatePublished - Jun 27 2015

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Proportional Hazards Models
Cause of Death
Kaplan-Meier Estimate
Fluorescent Antibody Technique
Neoplasms
Protein Isoforms
Biomarkers
Hormones
Drug Therapy
Survival
Population
Proteins

Keywords

  • Axillary node negative
  • Breast cancer
  • Mena
  • Metastasis
  • Prognostic marker

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Mena<sup>calc</sup>, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer. / Forse, Catherine L.; Agarwal, Seema; Pinnaduwage, Dushanthi; Gertler, Frank; Condeelis, John S.; Lin, Juan; Xue, Xiaonan (Nan); Johung, Kimberly; Mulligan, Anna Marie; Rohan, Thomas E.; Bull, Shelley B.; Andrulis, Irene L.

In: BMC Cancer, Vol. 15, No. 1, 483, 27.06.2015.

Research output: Contribution to journalArticle

Forse, Catherine L. ; Agarwal, Seema ; Pinnaduwage, Dushanthi ; Gertler, Frank ; Condeelis, John S. ; Lin, Juan ; Xue, Xiaonan (Nan) ; Johung, Kimberly ; Mulligan, Anna Marie ; Rohan, Thomas E. ; Bull, Shelley B. ; Andrulis, Irene L. / Mena<sup>calc</sup>, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer. In: BMC Cancer. 2015 ; Vol. 15, No. 1.
@article{4c86ebe8049c412c97577dacf1c0965d,
title = "Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer",
abstract = "Background: Menacalc is an immunofluorescence-based, quantitative method in which expression of the non-invasive Mena protein isoform (Mena11a) is subtracted from total Mena protein expression. Previous work has found a significant positive association between Menacalc and risk of death from breast cancer. Our goal was to determine if Menacalc could be used as an independent prognostic marker for axillary node-negative (ANN) breast cancer. Methods: Analysis of the association of Menacalc with overall survival (death from any cause) was performed for 403 ANN tumors using Kaplan Meier survival curves and the univariate Cox proportional hazards (PH) model with the log-rank or the likelihood ratio test. Cox PH models were used to estimate hazard ratios (HRs) for the association of Menacalc with risk of death after adjustment for HER2 status and clinicopathological tumor features. Results: High Menacalc was associated with increased risk of death from any cause (P = 0.0199, HR (CI) = 2.18 (1.19, 4.00)). A similarly elevated risk of death was found in the subset of the Menacalc cohort which did not receive hormone or chemotherapy (n = 142) (P = 0.0052, HR (CI) = 3.80 (1.58, 9.97)). There was a trend toward increased risk of death with relatively high Menacalc in the HER2, basal and luminal molecular subtypes. Conclusions: Menacalc may serve as an independent prognostic biomarker for the ANN breast cancer patient population.",
keywords = "Axillary node negative, Breast cancer, Mena, Metastasis, Prognostic marker",
author = "Forse, {Catherine L.} and Seema Agarwal and Dushanthi Pinnaduwage and Frank Gertler and Condeelis, {John S.} and Juan Lin and Xue, {Xiaonan (Nan)} and Kimberly Johung and Mulligan, {Anna Marie} and Rohan, {Thomas E.} and Bull, {Shelley B.} and Andrulis, {Irene L.}",
year = "2015",
month = "6",
day = "27",
doi = "10.1186/s12885-015-1468-6",
language = "English (US)",
volume = "15",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer

AU - Forse, Catherine L.

AU - Agarwal, Seema

AU - Pinnaduwage, Dushanthi

AU - Gertler, Frank

AU - Condeelis, John S.

AU - Lin, Juan

AU - Xue, Xiaonan (Nan)

AU - Johung, Kimberly

AU - Mulligan, Anna Marie

AU - Rohan, Thomas E.

AU - Bull, Shelley B.

AU - Andrulis, Irene L.

PY - 2015/6/27

Y1 - 2015/6/27

N2 - Background: Menacalc is an immunofluorescence-based, quantitative method in which expression of the non-invasive Mena protein isoform (Mena11a) is subtracted from total Mena protein expression. Previous work has found a significant positive association between Menacalc and risk of death from breast cancer. Our goal was to determine if Menacalc could be used as an independent prognostic marker for axillary node-negative (ANN) breast cancer. Methods: Analysis of the association of Menacalc with overall survival (death from any cause) was performed for 403 ANN tumors using Kaplan Meier survival curves and the univariate Cox proportional hazards (PH) model with the log-rank or the likelihood ratio test. Cox PH models were used to estimate hazard ratios (HRs) for the association of Menacalc with risk of death after adjustment for HER2 status and clinicopathological tumor features. Results: High Menacalc was associated with increased risk of death from any cause (P = 0.0199, HR (CI) = 2.18 (1.19, 4.00)). A similarly elevated risk of death was found in the subset of the Menacalc cohort which did not receive hormone or chemotherapy (n = 142) (P = 0.0052, HR (CI) = 3.80 (1.58, 9.97)). There was a trend toward increased risk of death with relatively high Menacalc in the HER2, basal and luminal molecular subtypes. Conclusions: Menacalc may serve as an independent prognostic biomarker for the ANN breast cancer patient population.

AB - Background: Menacalc is an immunofluorescence-based, quantitative method in which expression of the non-invasive Mena protein isoform (Mena11a) is subtracted from total Mena protein expression. Previous work has found a significant positive association between Menacalc and risk of death from breast cancer. Our goal was to determine if Menacalc could be used as an independent prognostic marker for axillary node-negative (ANN) breast cancer. Methods: Analysis of the association of Menacalc with overall survival (death from any cause) was performed for 403 ANN tumors using Kaplan Meier survival curves and the univariate Cox proportional hazards (PH) model with the log-rank or the likelihood ratio test. Cox PH models were used to estimate hazard ratios (HRs) for the association of Menacalc with risk of death after adjustment for HER2 status and clinicopathological tumor features. Results: High Menacalc was associated with increased risk of death from any cause (P = 0.0199, HR (CI) = 2.18 (1.19, 4.00)). A similarly elevated risk of death was found in the subset of the Menacalc cohort which did not receive hormone or chemotherapy (n = 142) (P = 0.0052, HR (CI) = 3.80 (1.58, 9.97)). There was a trend toward increased risk of death with relatively high Menacalc in the HER2, basal and luminal molecular subtypes. Conclusions: Menacalc may serve as an independent prognostic biomarker for the ANN breast cancer patient population.

KW - Axillary node negative

KW - Breast cancer

KW - Mena

KW - Metastasis

KW - Prognostic marker

UR - http://www.scopus.com/inward/record.url?scp=84933052257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84933052257&partnerID=8YFLogxK

U2 - 10.1186/s12885-015-1468-6

DO - 10.1186/s12885-015-1468-6

M3 - Article

VL - 15

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 483

ER -